Wall Street brokerages expect that Xencor, Inc. (NASDAQ:XNCR) will announce sales of $10.65 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Xencor’s earnings. The lowest sales estimate is $10.30 million and the highest is $11.00 million. Xencor posted sales of $6.44 million during the same quarter last year, which suggests a positive year-over-year growth rate of 65.4%. The firm is scheduled to announce its next earnings results on Tuesday, February 27th.
On average, analysts expect that Xencor will report full-year sales of $10.65 million for the current financial year, with estimates ranging from $25.10 million to $35.77 million. For the next fiscal year, analysts expect that the company will post sales of $25.33 million per share, with estimates ranging from $19.80 million to $36.20 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Xencor.
XNCR has been the subject of a number of recent research reports. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Canaccord Genuity set a $36.00 target price on Xencor and gave the stock a “buy” rating in a research note on Monday, October 23rd. BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $35.00 target price on shares of Xencor in a research note on Sunday, November 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. Xencor currently has an average rating of “Hold” and an average target price of $30.80.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can grew its holdings in shares of Xencor by 158.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 4,005 shares during the period. SG Americas Securities LLC boosted its holdings in Xencor by 62.6% during the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 3,252 shares during the period. Principal Financial Group Inc. purchased a new position in Xencor during the 3rd quarter valued at about $201,000. Legal & General Group Plc boosted its holdings in Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares during the period. Finally, Citadel Advisors LLC purchased a new position in Xencor during the 2nd quarter valued at about $224,000. Institutional investors and hedge funds own 77.61% of the company’s stock.
Shares of Xencor (NASDAQ XNCR) opened at $21.49 on Friday. Xencor has a 52 week low of $18.55 and a 52 week high of $29.38.
COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/02/brokerages-expect-xencor-inc-xncr-will-announce-quarterly-sales-of-10-65-million.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.